Patents by Inventor Susan D. Bromley

Susan D. Bromley has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMBINATION THERAPY WITH GLUTAMINASE INHIBITORS AND IMMUNO-ONCOLOGY AGENTS
    Publication number: 20210361649
    Abstract: The invention relates to methods of treating cancer, myeloproliferative diseases, or immunological or neurological diseases with a combination of a glutaminase inhibitor and an immuno-oncology therapeutic agent, such as an inhibitor of arginase, CTLA-4, indoleamine 2,3-dioxygenase, and/or PD-1/PD-L1.
    Type: Application
    Filed: March 4, 2021
    Publication date: November 25, 2021
    Inventors: Susan M. Molineaux, Matthew I. Gross, Susan D. Bromley, Francesco Parlati, Mark K. Bennett
  • Combination therapy with glutaminase inhibitors and immuno-oncology agents
    Patent number: 10940148
    Abstract: The invention relates to methods of treating cancer, myeloproliferative diseases, or immunological or neurological diseases with a combination of a glutaminase inhibitor and an immuno-oncology therapeutic agent, such as an inhibitor of arginase, CTLA-4, indoleamine 2,3-dioxygenase, and/or PD-1/PD-L1.
    Type: Grant
    Filed: February 1, 2019
    Date of Patent: March 9, 2021
    Assignee: Calithera Biosciences, Inc.
    Inventors: Susan M. Molineaux, Matthew I. Gross, Susan D. Bromley, Francesco Parlati, Mark K. Bennett
  • COMBINATION THERAPY WITH GLUTAMINASE INHIBITORS
    Publication number: 20200038398
    Abstract: The invention relates to methods of treating cancer or myeloproliferative diseases with a combination of a glutaminase inhibitor and a second anticancer agent such as osimertinib, pazopanib, navitoclax, palbociclib, or olaparib. The invention further relates to methods of treating cancer or myeloproliferative diseases with a combination of a glutaminase inhibitor and conventional radiotherapy or stereotactic body radiotherapy.
    Type: Application
    Filed: March 9, 2018
    Publication date: February 6, 2020
    Inventors: Susan D. Bromley, Francesco Parlati, Matthew I. Gross, Keith Orford
  • COMBINATION THERAPY WITH GLUTAMINASE INHIBITORS AND IMMUNO-ONCOLOGY AGENTS
    Publication number: 20190231776
    Abstract: The invention relates to methods of treating cancer, myeloproliferative diseases, or immunological or neurological diseases with a combination of a glutaminase inhibitor and an immuno-oncology therapeutic agent, such as an inhibitor of arginase, CTLA-4, indoleamine 2,3-dioxygenase, and/or PD-1/PD-L1.
    Type: Application
    Filed: February 1, 2019
    Publication date: August 1, 2019
    Inventors: Susan M. Molineaux, Matthew I. Gross, Susan D. Bromley, Francesco Parlati, Mark K. Bennett
  • Combination therapy with glutaminase inhibitors and immuno-oncology agents
    Patent number: 10258619
    Abstract: The invention relates to methods of treating cancer, myeloproliferative diseases, or immunological or neurological diseases with a combination of a glutaminase inhibitor and an immuno-oncology therapeutic agent, such as an inhibitor of arginase, CTLA-4, indoleamine 2,3-dioxygenase, and/or PD-1/PD-L1.
    Type: Grant
    Filed: October 4, 2016
    Date of Patent: April 16, 2019
    Assignee: Calithera Biosciences, Inc.
    Inventors: Susan M. Molineaux, Matthew I. Gross, Susan D. Bromley, Francesco Parlati, Mark K. Bennett
  • Combination therapy with glutaminase inhibitors
    Patent number: 10195197
    Abstract: The invention relates to novel heterocyclic compounds and pharmaceutical preparations thereof. The invention further relates to methods of treating or preventing cancer using the novel heterocyclic compounds of the invention.
    Type: Grant
    Filed: August 24, 2017
    Date of Patent: February 5, 2019
    Assignee: Calithera Biosciences, Inc.
    Inventors: Mark K. Bennett, Matthew I. Gross, Susan D. Bromley, Keith Orford
  • TREATMENT OF CANCER WITH INHIBITORS OF GLUTAMINASE
    Publication number: 20180055825
    Abstract: The invention relates to method of treating a disease or disorder (e.g., such as cancer) in a subject, comprising administering to the subject heterocyclic compounds and pharmaceutical preparations described herein, if the subject is determined to possess at least one G allele at single nucleotide polymorphism (SNP) rs6983267.
    Type: Application
    Filed: August 24, 2017
    Publication date: March 1, 2018
    Inventors: Yu Liang, Susan D. Bromley, Keith Orford
  • Combination Therapy with Glutaminase Inhibitors
    Publication number: 20180055842
    Abstract: The invention relates to novel heterocyclic compounds and pharmaceutical preparations thereof. The invention further relates to methods of treating or preventing cancer using the novel heterocyclic compounds of the invention.
    Type: Application
    Filed: August 24, 2017
    Publication date: March 1, 2018
    Inventors: Mark K. Bennett, Matthew I. Gross, Susan D. Bromley, Keith Orford
  • COMBINATION THERAPY WITH GLUTAMINASE INHIBITORS AND IMMUNO-ONCOLOGY AGENTS
    Publication number: 20170095473
    Abstract: The invention relates to methods of treating cancer, myeloproliferative diseases, or immunological or neurological diseases with a combination of a glutaminase inhibitor and an immuno-oncology therapeutic agent, such as an inhibitor of arginase, CTLA-4, indoleamine 2,3-dioxygenase, and/or PD-1/PD-L1.
    Type: Application
    Filed: October 4, 2016
    Publication date: April 6, 2017
    Inventors: Susan M. Molineaux, Matthew I. Gross, Susan D. Bromley, Francesco Parlati, Mark K. Bennett
  • TREATMENT OF CANCER WITH HETEROCYCLIC INHIBITORS OF GLUTAMINASE
    Publication number: 20150004134
    Abstract: The invention relates to novel heterocyclic compounds and pharmaceutical preparations thereof. The invention further relates to methods of treating or preventing cancer using the novel heterocyclic compounds of the invention.
    Type: Application
    Filed: December 3, 2013
    Publication date: January 1, 2015
    Applicant: CALITHERA BIOSCIENCES, INC.
    Inventors: Mark K. Bennett, Matthew I. Gross, Susan D. Bromley, Jim Li, Lijing Chen, Bindu Goyal, Guy Laidig, Timothy Friend Stanton, Eric Brian Sjogren